BCRX vs ARGX

For growth investors, BioCryst Pharmaceuticals, Inc.

(BCRX) is the stronger pick with 94. 1% revenue growth year-over-year, versus 90. 1% for argenx SE (ARGX). BioCryst Pharmaceuticals, Inc. (BCRX) offers the better valuation at 7. 4x trailing P/E (32. 9x forward), making it the more compelling value choice. Analysts rate BioCryst Pharmaceuticals, Inc. (BCRX) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, BioCryst Pharmaceuticals, Inc.

(BCRX) is the cheapest at 7. 4x versus argenx SE at 40. 1x. On forward P/E, argenx SE is actually cheaper at 30. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, argenx SE (ARGX) delivered a total return of +198.

6%, compared to -32. 2% for BioCryst Pharmaceuticals, Inc. (BCRX). Over 10 years, the gap is even starker: ARGX returned +33. 2% versus BCRX's +190. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), argenx SE (ARGX) is the lower-risk stock at 0.

52β versus BioCryst Pharmaceuticals, Inc. 's 0. 82β — meaning BCRX is approximately 57% more volatile than ARGX relative to the S&P 500.

By revenue growth (latest reported year), BioCryst Pharmaceuticals, Inc.

(BCRX) is pulling ahead at 94. 1% versus 90. 1% for argenx SE (ARGX). On earnings-per-share growth, the picture is similar: BioCryst Pharmaceuticals, Inc. grew EPS 381. 4% year-over-year, compared to 53. 6% for argenx SE. Over a 3-year CAGR, ARGX leads at 116. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

argenx SE (ARGX) is the more profitable company, earning 31.

1% net margin versus 30. 2% for BioCryst Pharmaceuticals, Inc. — meaning it keeps 31. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BCRX leads at 39. 0% versus 23. 4% for ARGX. At the gross margin level — before operating expenses — BCRX leads at 97. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, argenx SE (ARGX) trades at 30.

0x forward P/E versus 32. 9x for BioCryst Pharmaceuticals, Inc. — 2. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BCRX: 91. 0% to $17. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, argenx SE (ARGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52)). Both have compounded well over 10 years (ARGX: +33. 2%, BCRX: +190. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.